BIO-RAD LABORATORIES, INC. - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - February 26, 2013

Attached files

file filename
8-K - 8-K 2/26/2013 - BIO-RAD LABORATORIES, INC.bio-8k2262013.htm


Exhibit 99.1

Press Release


Bio-Rad Reports Fourth-Quarter and Full-Year 2012 Financial Results

HERCULES, CA - February 26, 2013 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2012.

Fourth-quarter reported revenues were $573.8 million, up 4.3% compared to $550.2 million reported for the fourth quarter of 2011. On a currency-neutral basis, quarterly revenues increased 6.1% compared to the same period in 2011. Fourth-quarter gross margin was 55.9% compared to 56.5% during the same quarter in 2011.

Net income for the fourth quarter of 2012 was $47.5 million, or $1.65 per share on a fully diluted basis, compared to $59.2 million, or $2.08 per share, respectively, during the same period in 2011. These results include a one-time gain of $4.3 million resulting from the sale of real property.

For the full year, sales were $2,069.2 million compared to $2,073.5 million in 2011. After normalizing for the impact of currency effects, full year revenues increased 3.6%.

Full-year net income was $169.2 million, or $5.91 per share on a fully diluted basis, compared to $178.2 million, or $6.26 per share, respectively, in 2011. The decrease in net income reflected lower gross margins and an increase in R&D expense. Full-year gross margin was 56.1% compared to 56.8% reported in 2011. Incremental gross profit for 2012 was impacted by additional amortization expense of $10.0 million related to acquisitions. Earnings were favorably impacted by a $16.1 million reduction in the valuation of contingent consideration associated with the Quantalife acquisition as well as an increase in other income resulting from certain investment gains.

“We are pleased with our performance in the fourth quarter, with good momentum across many of our product areas,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “As we had expected, full-year results reflect macroeconomic challenges which impacted many of our markets. Looking ahead to 2013, we anticipate a similar economic environment.”
(more)





Bio-Rad Reports Fourth-Quarter and Full-Year 2012 Financial Results
Page 2

Life Science
The Life Science segment net sales for the fourth quarter were $204.2 million, up 2.7% compared to the same period in 2011. On a currency-neutral basis, Life Science segment sales increased by 3.7%. Results for the fourth quarter benefitted from sales of process chromatography media and electrophoresis products as well the Company's QX100™ Droplet Digital™ PCR system. During the fourth quarter, the Company announced that it had signed a definitive agreement to acquire AbD Serotec, which provides a comprehensive catalog of antibodies. The purchase was completed in January of 2013. Also during the fourth quarter, Bio-Rad announced the launch of several new platforms, including the S3™ cell sorter and a series of new chromatography instruments. Full-year reported revenues for the Life Science segment were $688.4 million, down 0.9% compared to 2011, or an increase of 1.5% on a currency-neutral basis.

Clinical Diagnostics
The Clinical Diagnostics segment reported net sales of $365.9 million for the fourth quarter, up 5.3% compared to the same period in 2011. On a currency-neutral basis, net sales were up 7.5%. Performance in the Clinical Diagnostics segment in the fourth quarter reflects strength across all product lines, most notably the Company's quality controls, blood typing, and diabetes monitoring products. Full-year reported revenues for the Clinical Diagnostics segment were $1,365.5 million, up 0.1% compared to the same period in 2011. On a currency-neutral basis, full-year sales increased 4.7% compared to 2011.

2012 Full-Year Highlights
•
Full-year, sales were $2,069.2 million compared to $2,073.5 million in 2011. After normalizing for the impact of currency effects, full year revenues increased 3.6%.
•
Year-over-year net income was $169.2 million, or $5.91 per share on a fully diluted basis, compared to $178.2 million, or $6.26 per share in 2011.
•
In April, the company introduced its V3 Western Workflow™ system, which offers a portfolio of best-in-class products for electrophoresis, blotting, and imaging, saving researchers time and generating richer and more reliable data.
•
In July, Bio-Rad and Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics Inc., announced that they partnered to develop and distribute immunoassay kits. Under the terms of the agreement, Myriad RBM grants Bio‑Rad exclusive distribution rights, for research

(more)




Bio-Rad Reports Fourth-Quarter and Full-Year 2012 Financial Results
Page 3

purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio‑Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.
•
In August, Bio-Rad announced the launch of a Digital Biology Center to focus on the development of new products based on the Company's recently acquired droplet partitioning technology. The first product based on this technology, Bio‑Rad's QX100 Droplet Digital PCR system, applies a sample partitioning technology to polymerase chain reaction (PCR) offering a new approach to nucleic acid quantification.
•
In September, Bio-Rad introduced the TC20™ automated cell counter, the next generation of the TC10™ automated cell counter that provides accurate and reliable counts of live mammalian cells in 30 seconds.
•
Also during the third quarter, Bio-Rad acquired an automated benchtop cell sorting system from Propel Labs. The first shipments of the S3 Cell Sorter began during the first quarter of 2013.
•
In December, Bio-Rad announced that it had signed a definitive agreement to acquire AbD Serotec. The purchase was completed in January 2013.
•
Also in December, Bio-Rad announced that they had entered into an agreement with Lamprogen, Inc., granting Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles for use in a broad array of assays and research applications including flow cytometry.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) February 26, 2013. Interested parties may access the call by dialing 866-383-8008 (in the U.S.) or 617-597-5341 (international), access number 81335034. A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 15517550, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for replay for up to a year and may be accessed in the "Investor Relations" section of www.bio‑rad.com.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for the life science research and clinical

(more)
 




Bio-Rad Reports Fourth-Quarter and Full-Year 2012 Financial Results
Page 4


diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs approximately 7,300 people globally and had revenues exceeding $2 billion in 2012. For more information, please visit www.bio‑rad.com.
 

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Investor and Financial Contacts:
Bio-Rad Laboratories, Inc.
Christine Tsingos, Executive Vice President and Chief Financial Officer
Ron Hutton, Vice President and Treasurer
510-724-7000
investor_relations@bio-rad.com














Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

 
Three Months Ended
 
Year Ended
 
December 31,
 
December 31,
 
2012
 
2011
 
2012
 
2011
Net sales
$
573,839

 
$
550,238

 
$
2,069,235

 
$
2,073,529

Cost of goods sold
252,786

 
239,272

 
908,190

 
895,640

Gross profit
321,053

 
310,966

 
1,161,045

 
1,177,889

Selling, general and administrative expense
189,075

 
174,924

 
682,898

 
696,294

Research and development expense
59,777

 
50,112

 
214,040

 
186,439

Income from operations
72,201

 
85,930

 
264,107

 
295,156

Interest expense
11,765

 
11,987

 
49,263

 
53,135

Foreign exchange losses, net
1,532

 
1,710

 
5,040

 
13,842

Other (income) expense, net
(7,086
)
 
(1,676
)
 
(21,778
)
 
(7,583
)
Income before income taxes
65,990

 
73,909

 
231,582

 
235,762

Provision for income taxes
(18,567
)
 
(14,708
)
 
(62,279
)
 
(57,739
)
Net income including noncontrolling interests 
47,423

 
59,201

 
169,303

 
178,023

Net loss (income) attributable to noncontrolling interests
79

 
38

 
(69
)
 
200

Net income attributable to Bio-Rad
$
47,502

 
$
59,239

 
$
169,234

 
$
178,223

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
 
Net income per share basic attributable to Bio-Rad
$
1.67

 
$
2.11

 
$
5.98

 
$
6.36

Weighted average common shares - basic
28,394

 
28,131

 
28,290

 
28,031

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
 
Net income per share diluted attributable to Bio-Rad
$
1.65

 
$
2.08

 
$
5.91

 
$
6.26

Weighted average common shares - diluted
28,712

 
28,462

 
28,642

 
28,468


5

Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
(In thousands)


 
December 31,
2012
 
December 31,
2011
 
 (Unaudited)
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
463,388

 
$
574,231

Short-term investments
457,685

 
238,884

Accounts receivable, net
398,739

 
398,674

Inventories, net
448,370

 
433,510

Other current assets
156,612

 
152,856

Total current assets
1,924,794

 
1,798,155

 
 
 
 
Property, plant and equipment, net
416,938

 
349,501

Goodwill, net
495,418

 
468,933

Purchased intangibles, net
260,939

 
259,497

Other assets
333,527

 
220,717

Total assets
$
3,431,616

 
$
3,096,803

 
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
130,972

 
$
129,124

Accrued payroll and employee benefits
135,955

 
112,564

Notes payable and current maturities of long-term debt
1,750

 
814

Income and other taxes payable
32,271

 
52,285

Other current liabilities
160,292

 
164,328

Total current liabilities
461,240

 
459,115

 
 
 
 
Long-term debt, net of current maturities
732,414

 
731,698

Other long-term liabilities
221,237

 
161,608

Total liabilities
1,414,891

 
1,352,421

 
 
 
 
Bio-Rad stockholders’ equity
2,016,190

 
1,743,937

Noncontrolling interests
535

 
445

Total stockholders’ equity
2,016,725

 
1,744,382

Total liabilities and stockholders’ equity
$
3,431,616

 
$
3,096,803



6

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)


 
Year Ended
 
December 31,
 
2012
 
2011
 
(Unaudited)
 
 
Cash flows from operating activities:
 
 
 
Cash received from customers
$
2,063,805

 
$
2,018,755

Cash paid to suppliers and employees
(1,661,101
)
 
(1,656,467
)
Interest paid
(46,369
)
 
(56,859
)
Income tax payments
(87,434
)
 
(52,131
)
Other operating activities
9,997

 
6,518

Net cash provided by operating activities
278,898

 
259,816

Cash flows from investing activities:
 
 
 
Payments for acquisitions and long-term investments
(39,443
)
 
(158,538
)
Other investing activities
(373,361
)
 
(224,875
)
Net cash used in investing activities
(412,804
)
 
(383,413
)
Cash flows from financing activities:
 
 
 
Payments on long-term borrowings
(620
)
 
(226,835
)
Other financing activities
13,208

 
13,275

Net cash provided by (used in) financing activities
12,588

 
(213,560
)
Effect of foreign exchange rate changes on cash
10,475

 
4,837

Net decrease in cash and cash equivalents
(110,843
)
 
(332,320
)
Cash and cash equivalents at beginning of year
574,231

 
906,551

Cash and cash equivalents at end of year
$
463,388

 
$
574,231

Reconciliation of net income including noncontrolling interests to net cash provided by operating activities:
 
 
 
Net income including noncontrolling interests
$
169,303

 
$
178,023

Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:
 
 
 
Depreciation and amortization
130,424

 
120,956

Write off of goodwill
1,044

 
—

Changes in working capital
(11,487
)
 
(54,570
)
Other
(10,386
)
 
15,407

Net cash provided by operating activities
$
278,898

 
$
259,816


7

BIO-RAD LABORATORIES, INC. Reports